Karyopharm announces preliminary unaudited q4 and fy2019 product sales for xpovio

Karyopharm announces preliminary unaudited fourth quarter and full year 2019 product sales for xpovio® (selinexor) and provides commercial update.karyopharm therapeutics - expects net product sales of xpovio to be between $17 and $18 million during q4 2019.
KPTI Ratings Summary
KPTI Quant Ranking